Discussion
Izicopan, InflaRx’s experimental oral therapy for ANCA-associated vasculitis (AAV), was shown to reduce kidney damage in two different animal models of kidney injury. That’s according to data presented in a poster at the American Society of Nephrology’s Kidney Week 2026, held Oct. 21-25 in Denver. The poster was…